Search Prime Contracts

75N93023C00008

Definitive Contract

Overview

Government Description
"Multiplexed Droplet Digital Nucleic Acid Amplification Technologies For HIV Diagnosis"
Awardee
Vivid Bioinnovations, Pbc
Awarding / Funding Agency
National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN12 - Health R&D Services; Health Care Services; Applied Research
Place of Performance
San Francisco, CA 94107 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Est. Average FTE
1
Related Opportunity
SBIR PHS20231
Vivid Bioinnovations, Pbc was awarded Definitive Contract 75N93023C00008 (75N930-23-C-00008) for "Multiplexed Droplet Digital Nucleic Acid Amplification Technologies For Hiv Diagnosis" worth up to $299,903 by the National Institute of Allergy and Infectious Diseases in August 2023. The contract has a duration of 1 year and was awarded with a Small Business Total set aside with NAICS 541715 and PSC AN12 via direct negotiation acquisition procedures with 9 bids received.

SBIR Details

Research Type
Small Business Innovation Research Program (SBIR) Phase I
Title
""MULTIPLEXED DROPLET DIGITAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES FOR HIV DIAGNOSIS""
Abstract
Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a droplet digital nucleic acid test to diagnose HIV infection.
Research Objective
The goal of phase I is to establish the technical merit, feasibility, and commercial potential of proposed R&D efforts and determine the quality of performance of the small business awardee organization.
Topic Code
115
Agency Tracking Number
75N93023C00008
Solicitation Number
PHS-2023-1
Contact
Jessica Porter

Status
(Complete)

Last Modified 4/24/24
Period of Performance
8/1/23
Start Date
7/31/24
Current End Date
7/31/24
Potential End Date
100% Complete

Obligations
$299.9K
Total Obligated
$299.9K
Current Award
$299.9K
Potential Award
100% Funded

Award Hierarchy

Definitive Contract

75N93023C00008

Subcontracts

0

Activity Timeline

Interactive chart of timeline of amendments to 75N93023C00008

People

Suggested agency contacts for 75N93023C00008

Competition

Number of Bidders
9
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No

Other Categorizations

Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
Q1NZN4P95F83
Awardee CAGE
8BMG6
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhsjmathur
Last Modified By
hhsavirts
Approved By
hhsavirts

Legislative

Legislative Mandates
None Applicable
Performance District
CA-11
Senators
Dianne Feinstein
Alejandro Padilla
Representative
Nancy Pelosi

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) Health research and training Research and development contracts (25.5) $299,903 100%
Modified: 4/24/24